MAVIRET 50mg / 20mg coated granules in sachet medication leaflet

J05AP57 • glecaprevir + pibrentasvir • Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections

Glecaprevir/pibrentasvir is a fixed-dose combination medication used to treat hepatitis C.
It contains glecaprevir and pibrentasvir. It works against all six types of hepatitis C.
At twelve weeks following treatment between 81% and 100% of people have no evidence of hepatitis C.
It is taken once a day by mouth with food.

The most common side effects are headache, diarrhea, and tiredness.
In those with a history of hepatitis B, reactivation may occur. It is not recommended in people with moderate to severe liver disease.

Glecaprevir inhibits NS3/4A, a serine protease, and pibrentasvir inhibits NS5A, a zinc-binding hydrophilic phosphoprotein. Both of these proteins are essential in hepatitis C viral RNA replication, which can no longer take place upon inhibition of these proteins.

The combination was approved for medical use in the United States and Europe in 2017.
It is on the World Health Organization's List of Essential Medicines.